After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback